{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:49:22Z","timestamp":1790790562240,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1007\/s00280-006-0307-5","type":"journal-article","created":{"date-parts":[[2006,8,31]],"date-time":"2006-08-31T06:16:32Z","timestamp":1157004992000},"page":"643-650","source":"Crossref","is-referenced-by-count":34,"title":["Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis"],"prefix":"10.1007","volume":"59","author":[{"given":"Marcos Ven\u00edcio Alves","family":"Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Valdeci","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Yuri Bulc\u00e3o","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerly Anne","family":"de Castro Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronaldo Albuquerque","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,9,1]]},"reference":[{"key":"307_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0305-7372(85)90011-8","volume":"12","author":"WP Brade","year":"1985","unstructured":"Brade WP, Herdrich K, Varini M (1985) Ifosfamide\u2014pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1","journal-title":"Cancer Treat Rev"},{"key":"307_CR2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0305-7372(83)80005-X","volume":"10","author":"N Brock","year":"1983","unstructured":"Brock N, Pohl J (1983) The development of mesna for regional detoxification. Cancer Treat Rev 10:33\u201343","journal-title":"Cancer Treat Rev"},{"issue":"Suppl A","key":"307_CR3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0305-7372(83)80026-7","volume":"10","author":"H Burket","year":"1983","unstructured":"Burket H (1983) Clinical overview of mesna. Cancer Treat Rev 10(Suppl A):175\u2013181","journal-title":"Cancer Treat Rev"},{"key":"307_CR4","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/0006-2952(79)90222-3","volume":"28","author":"PJ Cox","year":"1979","unstructured":"Cox PJ (1979) Cyclophosphamide cystitis\u2014identification of acrolein as the causative agent. Biochem Pharmacol 28:2045\u20132049","journal-title":"Biochem Pharmacol"},{"key":"307_CR5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2165\/00003495-199142030-00006","volume":"42","author":"KL Dechant","year":"1991","unstructured":"Dechant KL, Brogden RN, Pilkington T, Faulds D (1991) Ifosfamide\/Mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42:428\u2013467","journal-title":"Drugs"},{"key":"307_CR6","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/S0022-5347(01)68238-7","volume":"158","author":"O Etlik","year":"1997","unstructured":"Etlik O, Tomur A, Deveci S, Piskin I, Pekcan M (1997) Comparison of uroprotective efficacy of Mesna and HBO treatments in cyclophosphamide-induced hemorrhagic cystitis. J Urol 158:2296\u20132299","journal-title":"J Urol"},{"key":"307_CR7","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/archinte.1976.03630050090015","volume":"136","author":"BSI Foad","year":"1976","unstructured":"Foad BSI, Hess EV (1976) Urinary bladder complications with cyclophosphamide therapy. Arch Intern Med 136:616\u2013619","journal-title":"Arch Intern Med"},{"key":"307_CR8","first-page":"1103","volume":"28","author":"TNA Gomes","year":"1995","unstructured":"Gomes TNA, Santos CC, Souza-Filho MVP, Cunha FQ, Ribeiro RA (1995) Participation of TNF-\u03b1 and IL-1 in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. Braz J Med Biol Res 28:1103\u20131108","journal-title":"Braz J Med Biol Res"},{"key":"307_CR9","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1200\/JCO.1999.17.10.3333","volume":"17","author":"ML Hensley","year":"1999","unstructured":"Hensley ML, Schuchter ML, Lindley C, Meropol NJ et al (1999) American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 17:3333\u20133355","journal-title":"J Clin Oncol"},{"key":"307_CR10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0749-2081(89)90084-3","volume":"5","author":"D Higgs","year":"1989","unstructured":"Higgs D, Nagy C, Einhorn LH (1989) Ifosfamide: a clinical review. Semin Oncol Nurs 5:70\u201377","journal-title":"Semin Oncol Nurs"},{"key":"307_CR11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1152\/ajpregu.00465.2002","volume":"284","author":"VY Hu","year":"2003","unstructured":"Hu VY, Malley S, Dattilio A, Folsom SB, Zvara P, Vizzard MA (2003) COX-2 and prostanoid expression in micturition pathways after cyclophosphamide-induced cystitis in the rat. Am J Physiol Regul Integr Comp Physiol 284:574\u2013585","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"307_CR12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0022-5347(17)44929-9","volume":"133","author":"KJ Gray","year":"1986","unstructured":"Gray KJ, Engelmann UH, Johnson EH, Fishman IJ (1986) Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy. J Urol 133:497\u2013500","journal-title":"J Urol"},{"key":"307_CR13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF01202226","volume":"121","author":"A Katz","year":"1995","unstructured":"Katz A, Epelman S, Anelli A et al (1995) A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. J Cancer Res Clin Oncol 121:128\u2013131","journal-title":"J Cancer Res Clin Oncol"},{"key":"307_CR14","first-page":"5829","volume":"9","author":"JR Mace","year":"2003","unstructured":"Mace JR, Keohan ML, Bernardy H, Junge K, Niebch G et al (2003) Crossover randomized comparison of intravenous versus intravenous\/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. Clin Cancer Res 9:5829\u20135834","journal-title":"Clin Cancer Res"},{"key":"307_CR15","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1590\/S0100-879X1999001000006","volume":"32","author":"MM Morais","year":"1999","unstructured":"Morais MM, Belarmino-Filho JN, Brito GAC, Ribeiro RA (1999) Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis\u2014comparison of the effects of dexamethasone and Mesna. Braz J Med Biol Res 32:1211\u20131215","journal-title":"Braz J Med Biol Res"},{"key":"307_CR16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0022-5347(17)57129-3","volume":"120","author":"R Pyeritz","year":"1978","unstructured":"Pyeritz R, Droller MJ, Bender WL, Saral R (1978) An approach to control of massive hemorrhage in cyclophosphamide-induced cystitis by intravenous vasopressin: a case report. J Urol 120:253\u2013254","journal-title":"J Urol"},{"key":"307_CR17","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0022-5347(01)63832-1","volume":"159","author":"TR Ratliff","year":"1998","unstructured":"Ratliff TR, Willians RD (1998) Hemorrhagic cystitis, chemotherapy, and bladder toxicity. J Urol 159:1044","journal-title":"J Urol"},{"key":"307_CR18","first-page":"2229","volume":"150","author":"RA Ribeiro","year":"2002","unstructured":"Ribeiro RA, Freitas HC, Campos MC et al (2002) Tumor necrosis factor-\u03b1 and interleukin-1\u03b2 mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. J Urol 150:2229\u20132234","journal-title":"J Urol"},{"key":"307_CR19","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1200\/JCO.1991.9.11.2016","volume":"11","author":"JD Shepherd","year":"1991","unstructured":"Shepherd JD, Pringle LE, Barnett MJ, Klingemann HG, Reece DE, Phillips GL (1991) Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 11:2016\u20132020","journal-title":"J Clin Oncol"},{"key":"307_CR20","first-page":"247","volume":"150","author":"MVP Souza-Filho","year":"1997","unstructured":"Souza-Filho MVP, Lima MVA, Pompeu MML, Ballejo G, Cunha FQ, Ribeiro RA (1997) Involvement of nitric oxide in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis. Am J Pathol 150:247\u2013256","journal-title":"Am J Pathol"},{"key":"307_CR21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000281847","volume":"42","author":"H Theman","year":"1987","unstructured":"Theman H, Oberdorf E, Brock N, Pohl J (1987) Electron microscopic investigations of cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna. Urol Int 42:37\u201343","journal-title":"Urol Int"},{"issue":"11","key":"307_CR22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1442-2042.2003.00709.x","volume":"10","author":"MM Vieira","year":"2003","unstructured":"Vieira MM, Brito GA, Belarmino-Filho JN, Macedo FY, Nery EA, Cunha FQ, Ribeiro RA (2003) Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. Int J Urol 10(11):595\u2013602","journal-title":"Int J Urol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0307-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-006-0307-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0307-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:06:23Z","timestamp":1559023583000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-006-0307-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["307"],"URL":"https:\/\/doi.org\/10.1007\/s00280-006-0307-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,1]]}}}